Ameren Free cash flow decreased by 2035.2% to -$1.15B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 82.1%, from -$633.00M to -$1.15B. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a -19.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$405.00M | -$94.00M | -$397.00M | -$386.00M | -$280.00M | -$172.00M | -$250.00M | -$435.00M | -$276.00M | $171.00M | -$493.00M | -$398.00M | -$445.00M | -$240.00M | -$473.00M | -$633.00M | -$204.00M | $116.00M | -$54.00M | -$1.15B |
| QoQ Change | — | +76.8% | -322.3% | +2.8% | +27.5% | +38.6% | -45.3% | -74.0% | +36.6% | +162.0% | -388.3% | +19.3% | -11.8% | +46.1% | -97.1% | -33.8% | +67.8% | +156.9% | -146.6% | <-999% |
| YoY Change | — | — | — | — | +30.9% | -83.0% | +37.0% | -12.7% | +1.4% | +199.4% | -97.2% | +8.5% | -61.2% | -240.4% | +4.1% | -59.0% | +54.2% | +148.3% | +88.6% | -82.1% |